PMID- 34709083
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20220321
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 13
IP  - 17
DP  - 2021 Dec
TI  - Association between PD-L1 inhibitor, tumor site and adverse events of potential 
      immune etiology within the US FDA adverse event reporting system.
PG  - 1407-1417
LID - 10.2217/imt-2021-0068 [doi]
AB  - Objective: To analyze tumor- and treatment-related factors that might impact the 
      development of certain adverse events (AEs) of potential immune etiology among 
      patients receiving PD-L1 inhibitors. Methods: The FDA Adverse Event Reporting 
      System (FAERS) was accessed, and AE reports related to the use of PD-L1 
      inhibitors were reviewed. Associations between treatment, tumor type and 
      occurrence of AEs of special interest were analyzed through multivariable 
      logistic regression analysis. Results: A total of 80,304 AE reports were included 
      in the current analysis. Diagnosis with lung cancer was associated with a higher 
      probability of pneumonitis; diagnosis with melanoma was associated with a higher 
      probability of hepatitis, hypophysitis/hypopituitarism and uveitis; and diagnosis 
      with genitourinary cancers was associated with a higher probability of nephritis, 
      adrenal insufficiency and myocarditis. Conclusion:  Within this cohort limited to 
      AEs reported to the FAERS, there is an association between different AEs of 
      special interest, agent(s) used and tumor(s) treated.
FAU - Abdel-Rahman, Omar
AU  - Abdel-Rahman O
AUID- ORCID: 0000-0002-5117-2502
AD  - Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, 
      AB, T6G 1Z2, Canada.
LA  - eng
PT  - Journal Article
DEP - 20211028
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - *Adverse Drug Reaction Reporting Systems
MH  - Aged
MH  - Female
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/administration & dosage/adverse effects
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Melanoma/*drug therapy
MH  - Middle Aged
MH  - Neoplasm Proteins/*antagonists & inhibitors
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - United States
MH  - United States Food and Drug Administration
OAB - Lay abstract The current study sought to examine whether the type of cancer 
      treated and/or type of immunotherapy received might be associated with side 
      effects that patients can experience with a certain type of immunotherapy called 
      PD-L1 inhibitors. It is suggested that there is a considerable variability in the 
      way different individuals might develop those adverse events, and that the 
      specific immunotherapy used and the specific cancer treated might affect the 
      chance that an individual would develop a certain adverse event as a result of 
      immunotherapy.
OABL- eng
OTO - NOTNLM
OT  - FAERS
OT  - PD-L1 inhibitors
OT  - adverse events
OT  - irAEs
OT  - tumor sites
EDAT- 2021/10/29 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/10/28 12:17
PHST- 2021/10/29 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/10/28 12:17 [entrez]
AID - 10.2217/imt-2021-0068 [doi]
PST - ppublish
SO  - Immunotherapy. 2021 Dec;13(17):1407-1417. doi: 10.2217/imt-2021-0068. Epub 2021 
      Oct 28.